AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease by | Oct 17, 2024 | Uncategorized Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.